In treatment-naive patients with low disease activity RA, which DMARD is preferred?

• A. Methotrexate
• B. Hydroxychloroquine (HCQ)
• C. Sulfasalazine
• D. Leflunomide

Answer: (B)

In RA, choosing a DMARD for someone who is treatment-naive with low disease activity centers on balancing safety with effectiveness. For mild disease, a DMARD with a very favorable safety and tolerability profile is preferred, so you can start disease modification without adding unnecessary toxicity.

Hydroxychloroquine fits this well. It has a long track record of safety, is generally well tolerated, and carries minimal risk of serious organ toxicity or cytopenias compared with other DMARDs. It is also considered safe in pregnancy and lactation, which broadens its suitability in early RA when disease activity is not high. While it works more slowly than methotrexate, its gentle safety profile makes it a reasonable initial choice in patients with only mild activity, especially when you want to avoid the higher monitoring burden and potential adverse effects associated with more potent DMARDs. Regular ophthalmologic screening is important with HCQ because of the small but real risk of retinal toxicity with long-term use.

Other DMARDs like methotrexate are more potent but carry higher risks—liver toxicity, cytopenias, mucosal ulcers, and teratogenic concerns—and require closer lab monitoring and folate supplementation. Sulfasalazine and leflunomide also have notable adverse effects and monitoring considerations (GI intolerance, hepatotoxicity, teratogenicity), which makes them less ideal as initial therapy in a patient with low disease activity. Thus, the safer, well-tolerated profile of hydroxychloroquine makes it the preferred starting DMARD in this scenario.